



IMMUNOLOGICAL ASPECTS AND ANTI-AMYLOID 
STRATEGY FOR ALZHEIMER’S DEMENTIA
Rajka M. LIŠČIĆ
Institute for Medical Research and Occupational Health, Zagreb, Croatia
Received in June 2013
CrossChecked in June 2013
Accepted in September 2013
Alzheimer’s dementia (AD) is the most common form of dementia among the elderly, accounting for at 
least two-thirds of all dementia cases. It represents a costly burden, since its global prevalence is estimated 
at 24 million cases. Amyloid beta or Aβ plaques and neurofi brillary tangles defi ne AD pathologically but 
do not fully explain it, because dementia may also be caused by infl ammation resulting in neuronal, axonal 
synaptic loss and dysfunction. An important component of AD pathophysiology are amyloid plaques 
surrounded by activated microglia, cytokines, and complement components, suggesting infl ammation. In 
the diagnosis of AD, cerebrospinal fl uid markers, especially in vivo amyloid measurements, contribute to 
an accurate assessment of AD pathology and differential diagnosis. Aβ levels are a very good marker for 
the presence of amyloid deposits in the brain, while total tau and phosphorylated tau are useful for the 
detection of neurodegeneration. The implementation of anti-amyloid therapy and other disease-modifying 
interventions may have immense clinical impact if initiated at an early or presymptomatic stage of AD, 
before signifi cant brain damage occurs. This paper briefl y reviews the abovementioned topics and provides 
recommendations for future studies.
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Alzheimer’s dementia (AD) is a progressive 
degenerative disease of the brain and the most 
common cause of dementia among elderly persons, 
accounting for at least two-thirds of all dementia cases 
(1, 2). The global prevalence of dementia is estimated 
to be as high as 24 million cases and is predicted to 
double every 20 years by 2040, which will undoubtedly 
lead to an even higher and more costly burden than at 
present (3). AD is generally defi ned as a progressive 
decline in cognitive functions which typically begins 
with memory impairment and a characteristic change 
in personality and executive functions. Before death, 
individuals usually become dependent on caregivers. 
There is no available cure.
The neuropathological hallmarks of an AD brain 
include diffuse and neuritic extracellular plaques 
composed of amyloid beta (Aβ) peptides (Figure 1), 
which are frequently surrounded by dystrophic 
neurites and intraneuronal neurofibrillary tangles 
(NFT), which are in turn composed of paired helical 
fi laments or phosphorylated tau proteins (4). These 
hallmark pathologies are often accompanied by 
reactive microgliosis and neuron and synapse loss. 
The aetiological mechanisms underlying the 
neuropathological changes in AD still remain unclear 
but are probably affected by environmental, genetic, 
and neuroinfl ammatory factors (3). 
Up to 3 % of AD cases are caused by an autosomal 
dominant mutation with three thus far identifi ed genes: 
the amyloid precursor protein (APP), presenilin 1 
(PSEN 1), and presenilin 2 (PSEN 2) (5). The Aβ 
peptide is cleaved from the APP by the sequential 
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activities of β-secretase and γ-secretase enzymes. Aβ 
occurs in multiple forms, including those ranging from 
37 to 43 amino acids in length. Among these, Aß42 
seems to be essential for initiating Aβ aggregation and 
is considered central to the amyloid cascade hypothesis 
of AD (6, 7). The APOE ε4 allele is the most important 
genetic risk factor for sporadic AD (8).
Infl ammation mediated by activated microglia is 
an important component of AD pathophysiology (9) 
and neuritic plaques are the foci of the local 
infl ammatory response (10). Aβ neuritic plaques are 
surrounded by activated microglia, cytokines, and 
complement components,  which are called 
„inflammatory foci”. In contrast, diffuse plaques 
without reactive microglia are considered clinically 
benign Aβ deposits.
These objectively measured AD biomarkers are 
useful for the diagnosis, longitudinal assessment, and 
evaluation of the subsequent therapeutic response. Aβ, 
one of the most frequently used biomarkers, is 
produced in neurons and secreted into the brain’s 
extracellular space. Measurements of cerebrospinal 
fl uid (CSF) amyloid peptide levels can indicate the 
extent of peptide generation and clearance in the brain, 
particularly in radio-labelled amino acid infusion 
studies (11). The mean concentration of Aβ42, a major 
component of Aß, in the CSF was reduced by as much 
as 50 % in AD subjects relative to age-matched 
controls (12), as the result of Aβ deposition in amyloid 
plaques, which prevented its transit from the brain into 
the CSF. In support of this hypothesis, all individuals 
with Aß deposits showed low concentrations of Aß in 
the CSF regardless of their cognitive status (13-15). 
However, CSF Aβ does not correlate well with disease 
duration or severity (6), which is consistent with 11C-
labeled Pittsburgh Compound B (11C-PIB) results from 
a study that showed that amyloid retention does not 
change signifi cantly during the symptomatic stages of 
AD (16), and further supports the fi nding that amyloid 
pathology occurs very early in the process of this 
disease (6). Thus, CSF Aß can serve as a diagnostic 
and surrogate biomarker for Aß deposition in the brain. 
The decrease in CSF Aß appears to precede amyloid 
retention as detected by amyloid imaging using 11C-
PIB, signifying what is perhaps the fi rst indication of 
AD pathology in cognitively normal individuals (13, 
15, 17). 
Tau is a major protein component of, at least 
initially, intraneuronal NFT and is elevated in the CSF 
of most AD patients. In addition, it has been shown 
that total tau (T-tau) levels in the CSF can rapidly 
increase following neuronal injury, indicating the 
severity of the underlying neurodegeneration (15). 
T-tau, as a biomarker of neuronal injury, can transiently 
increase after any acute brain injury, such as stroke or 
physical trauma (16). The abnormal phosphorylated 
tau (p-tau) (17) has increased specificity for 
discriminating AD from other dementias [e.g., fronto-
temporal dementia or dementia with Lewy body 
(DLB) (2, 18) and non-demented controls (11)]. 
Distinguishing DLB from AD is a major clinical 
challenge due to different optimal management, 
allowing for the initiation of effective pharmacotherapy 
and avoiding neuroleptic sensitivity. The deposition 
of Aβ peptides drives cerebral neuroinfl ammation by 
activating microglia. Indeed, Aβ activation of the 
NLRP3 infl ammasome in microglia is fundamental 
for interleukin-1β (IL-1B) maturation and subsequent 
infl ammatory events. However, it remains unknown 
whether the NLRP3 infl ammasome, which leads to 
the production of the pro-infl ammatory IL-1B, thus 
indicating an infl ammatory process, plays a role in the 
progression of AD (22). On an animal model, 
behavioural and cognitive functions were improved 
by reducing the signalling from this particular 
infl ammasome, making infl ammasomes a promising 
therapeutic target for AD therapy (22). Chronic 
infl ammation coupled with neuronal ageing induces 
cellular stress and concomitant impairments in basic 
neuronal functions. The beneficial side of the 
Figure 1  The evolution of plaques in Alzheimer’s disease. 
Diffuse plaques, also called benign plaques, occur 
much earlier than neuritic plaques, thus supporting 
the idea of a therapeutic intervention in the early 
stage of the disease. (Courtesy of Professor Nigel J 
Cairns, PhD, Washington University in St Louis, MO, 
USA) 
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infl ammation immune system against amyloids is the 
reduction of Aβ and the immunization against Aβ.
Today’s anti-amyloid strategies include immune 
therapies and vaccines for amyloid clearance, plaque 
busters, and amyloid clearance enhancers. These drugs 
are designed as an antibody to bind Aβ. The stimulation 
of Aβ clearance from the brain of AD patients via the 
administration of Aβ antigens (active vaccination) or 
anti-Aβ monoclonal amyloid antibodies (passive 
vaccination) has already been applied. In 2001, the 
fi rst clinical trial with the Aβ peptide active vaccine 
(AN1792, consisting of preaggregate Aβ and an 
immune adjuvant, QS-21) was initiated. After the 
second dose, however, meningoencephalitis occurred 
in 5 % to 6 % of immunized patients, and the trial was 
stopped. The clearance of Aβ from the human brain, 
however, was successful (23), suggesting that the 
immune response generated against the peptide 
elicited the clearance of Aβ plaques. Passive 
immunotherapy with anti-amyloid substances is 
currently in development. 
Bapineuzumab (β-amyloid peptide (i) neutralizing 
(u) monoclonal antibody), was designed to bind to Aβ 
in patients with mild-to-moderate forms of AD, but 
all Phase III clinical trials of bapineuzumab have been 
halted in 2012, because the drug did not meet the 
endpoints for cognition and global function (24). Also, 
the occurrence of vasogenic oedema after 
b a p i n e u z u m a b ,  a n d  m o r e  r a r e l y  b r a i n 
microhaemorrhages (especially in Apo E ε4 carriers), 
has raised concerns about the safety of these antibodies 
directed against the N-terminus of Aβ. Recently, 
solanezumab (soluble amyloid neutralizing (u) 
monoclonal antibody), a humanized anti-Aβ 
monoclonal antibody directed against the Aβ peptide, 
was shown to neutralize soluble Aβ species, thus 
becoming the fi rst therapeutic drug to be evaluated in 
the anti-amyloid treatment in asymptomatic AD (25). 
This was the fi rst application of an Aβ clearing drug 
in older people thought to be in the presymptomatic 
stage of AD with evidence of amyloid in their brains 
shown by 11C-labeled PIB imaging (26), but with no 
clinical symptoms of the disease yet. The clearance 
of plaques, however, has not yet been shown to reverse 
memory in clinical trials, even though many scientists 
in the fi eld feel that immunotherapy holds promise. 
The failure of bapineuzumab to produce benefi ts has 
aroused some scepticism about the amyloid cascade 
hypothesis (3), which holds that toxic amyloid proteins 
cleaved from the APP initiate AD (Figure 2). 
Recently, a coding mutation (A673T) found in the 
APP gene conferred strong protection against AD even 
in people who carried the APOE4 gene, therefore 
demonstrating the importance of keeping Aβ levels in 
the brain low (1). The discovery of the protective APP 
mutation in approx. 1 % of Icelanders suggested that 
lowering amyloids in the brain, either with anti-
amyloid therapy or some other treatment, must begin 
long before the symptoms of AD set in. As a result, 
the levels of Aβ in the CSF began to decline 25 years 
before the expected onset of symptoms, which is a 
signal that the protein is being sequestered in the brain 
Figure 2 The Amyloid Cascade Hypothesis (from Reitz C; Int J Alzheimers Dis 2012, 2012:369808)
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as insoluble plaque, as shown in a group of 128 
participants from the prospective and longitudinal 
Dominantly Inherited Alzheimer Network (DIAN) 
study on early onset AD (27). Several grants for 
Alzheimer’s prevention studies were recently awarded 
by the US National Institutes of Health (NIH) in order 
to test anti-amyloid drugs on members of a Colombian 
family, the largest extended family in the world with 
a gene mutation that causes them to develop AD early, 
showing cognitive impairment by around age 45, and 
full dementia several years later. In this trial, family 
members as young as 30 will receive another anti-
amyloid monoclonal antibody called crenezumab (25). 
So far, three investigational monoclonal antibodies 
against amyloids have been selected for clinical trials 
that will try to prevent dementia in people who are on 
the path to AD due to an inherited autosomal-dominant 
mutation (28).
In the majority of cases (97 %) involving late-onset 
AD caused by a number of risk-factor genes, 
identifying these genes will be the greatest advancement 
towards effective treatment. Based on the new 
diagnostic criteria for AD (26, 29) and recent 
experience with major failures of anti-Aβ drugs in 
mild-to-moderate AD patients, one could argue that 
clinical trials on potential disease-modifying drugs, 
including immunological approaches, should be 
performed in the early or preclinical stages of AD, 
years before the fi rst symptoms occur (30). 
In summary, despite tremendous investments in 
basic and clinical research, no cure or preventive 
treatment for Alzheimer’s dementia has been yielded. 
The amyloid-beta (Aβ) peptide has become a major 
therapeutic target in AD. The genetic mutations cause 
increased Aβ levels, followed by amyloidosis, 
tauopathy, brain atrophy, and decreased metabolism. 
Infl ammatory processes are strongly correlated with 
the onset and progression of AD in humans, and could 
have a pivotal role in AD aetiology. Based on the new 
diagnostic criteria and recent experiences with anti-Aβ 
drugs in early-stage AD patients, one could argue that 
the treatment for AD patients should start years before 
the fi rst onset of clinical symptoms.
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Sažetak
IMUNOLOŠKI ASPEKTI I ANTIAMILOIDNE STRATEGIJE ZA ALZHEIMEROVU DEMENCIJU
Alzheimerova bolest (AB) najučestaliji je oblik demencije u starijih: najmanje dvije trećine sveukupnih 
slučajeva demencija upravo je AB. Prevalencija bolesti u svijetu procjenjuje se na 24 milijuna slučajeva, 
što je značajno fi nancijsko opterećenje. Amiloidni beta (Aβ) plakovi (eng. amyloid plaques) i neurofi brilarni 
snopići (eng. neurofi brillary tangles) glavne su patološke karakteristike AB-a, jer uključuju i upalu, 
neuronalnu leziju te gubitak odnosno disfunkciju aksona i sinapsa. Amiloidni plakovi okružuju aktiviranu 
mikrogliju, citokine i komponente komplementa, što je pokazatelj upale, koja je važna karika u patofi ziologiji 
AB-a. Prilikom  dijagnosticiranja AB-a važnu ulogu imaju markeri likvora i in vivo detekcija amiloida u 
mozgu, koji pridonose optimalnoj procjeni patologije ove bolesti i njene diferencijalne dijagnoze. Za 
detekciju amiloida u mozgu koristi se Aβ u cerebrospinalnom likvoru, a za detekciju neurodegenerativnih 
promjena iznimno su važni total-tau (T-tau) i fosforilirani-tau (p-tau) markeri. Uvođenje antiamiloidne i 
ostalih terapija moglo bi imati značajne pozitivne kliničke učinke ako bi se s terapijom započelo rano i/ili 
u presimptomatskoj fazi bolesti, prije nego dođe do značajnog gubitka neurona. U ovom radu dan je kratak 
prikaz spomenutih tema, uz osvrt na aktualna i buduća istraživanja i kliničke studije primjenom 
monoklonalnih protutijela protiv amiloida kao mogućih uzročnika AB-a u početnoj i/ili ranoj fazi 
bolesti.
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